"EC approves GSK’s Jemperli-chemo combo for endometrial cancer" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on t

GSK plc GSK announced that the European Commission has granted approval for the expanded use of Jemperli (dostarlimab) plus chemotherapy to include all adult patients with primary, advanced or recurrent endometrial cancer.

Meanwhile, J&J has claimed EU approval for its combination of EGFRxMET bispecific antibody Rybrevant (amivantamab) with third-generation EGFR tyrosine kinase inhibitor Lazcluze (lazertinib) as a first-line treatment for locally advanced and metastatic NSCLC with exon 19 deletions or exon 21 L858R substitutions.

GSK's Jemperli wins EU approval for broader use in advanced endometrial cancer, showing improved survival and significant trial results.

GSK’s Jemperli is designed to help the body’s immune system find and attack cancer cells, and is already approved in the EU to treat certain adults with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) endometrial cancer.

London: GSK plc has announced the European Commission has approved Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult